2Peerlinck K,De Lepeleire I,Goldberg M,et al.A selective nonpeptide platelet glycoprotein Ⅱb/Ⅲa antagonist,it active in man[J].Circulation,1993,88(4):1512.
3Coller BS,Peerschke EI,Scudder LE,et al.A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombosthenic like state in normal platelets and binds to glycoproteins Ⅱb and/or Ⅲa[J].J Clin Invest,1983,72:325.
4Randomised placebo controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-Ⅱb/Ⅲa blockade.The EPISTENT Investigators.Evaluation of platelet Ⅱb/Ⅲa inhibitor for stenting[J].Lancet,1998,352:87.
5The EPIC Investigators.Use of monoclonal antibody directed against the platelet glycoprotein Ⅱb/Ⅲa receptor in high-risk coronary angioplasty[J].N Engl J Med,1994,330(14):956.
6Simoons ML.GUSTO Ⅳ-ACS Investigators.Effect of Glycoprotein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO Ⅳ-ACS randomised trial[J].Lancet,2001,357 (9272):1915.
7Scarborough RM,Naughton MA,Teng W,et al.Design of potent and specific integrin antagonists.Peptide antagonists with high specificity for glycoprotein Ⅱb/Ⅲa[J].J Biol Chem,1993,268:1066.
8Jennings L,Tardiff B,Philips D,et al.Comparison of recept or occupancy and platelet aggregation response of epifibatide administered intravenously in patients with unstable angina or non Q wave myocardial infarction[J].J Am Coll Cardiol,1998,31(2A):93A.
9Mahaffey KW,Harrington RA,Simoons ML,et al.Stroke in patients with acute coronary syndromes:incidence and outcomes in the platelet glycoprotein Ⅱb/Ⅲa in unstable angina.Receptor suppression using integrilin therapy (PURSUIT) trial.The PURSUIT Investigators[J].Circulation,1999,99 (18):2371.
10Egberston MS,Chang CT,Duggan ME,et al.Nonrrpeptide fibrinogen receptor antagonist 2.Optimization of a tyrosine template a mimic for Arg-Gly -Asp[J].J Med Chem,1994,37:2537.
1Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke a combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial[J ]. Stroke, 2000, 31 (6): 12,40-1249.
2Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo- controlled trial [J]. Lancet, 2004, 364(9431 ): 331-337.
3Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J]. N EnglJ Med 2006, 354(16): 1706-1707.
4SPS3 Investigators, Benavente OR, Hart RG, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke[J]. Y EnglJ Med, 2012, 367(9): 817-825.
5Hankey GJ, Johnston SC, Easton JD, et al. Effect of clopidogrel plus ASA rs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial[J]. Int J Stroke, 2011, 6(1): 3-9.
6Kennedy J, Hill MD, Ryckborst KJ, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial[J]. Lancet Neurol, 2007, 6(11): 961-969.
7Cohen SN. Letter regarding article by Markus et al, "Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic cardiac stenosis evaluated using doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial"[J]. Circulation, 2005, 112(20): e325.
8Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial[J]. Lancet Neurol, 2010, 9(5) : 489-497.
9Wang Y, Johnston SC, CHANCE Investigators. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patientswith acute nondisabling cerebrovascular event[J]. Am Heart J, 2010, 160(3): 380-386.
10The Clinical Coordinator Center (CCC) based in the UCSF Stroke Sciences Group (SSG), and the NINDS NETT Network. Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial. http://www.pointtrial.org/.
